Epilepsy - Pipeline Review, H1 2020

February 2020 | 605 pages | ID: E045D88EDC0EN
Global Markets Direct

Abstracts

Epilepsy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H1 2020, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 8, 28, 25, 4, 93, 24 and 6 respectively. Similarly, the Universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 2, 23 and 3 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Epilepsy - Overview
Epilepsy - Therapeutics Development
Epilepsy - Therapeutics Assessment
Epilepsy - Companies Involved in Therapeutics Development
Epilepsy - Drug Profiles
Epilepsy - Dormant Projects
Epilepsy - Discontinued Products
Epilepsy - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Epilepsy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Epilepsy - Pipeline by Aadi Bioscience Inc, H1 2020
Epilepsy - Pipeline by Advanced Neural Dynamics Inc, H1 2020
Epilepsy - Pipeline by Advicenne SA, H1 2020
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc, H1 2020
Epilepsy - Dormant Projects, H1 2020
Epilepsy - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Epilepsy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Aadi Bioscience Inc
Advanced Neural Dynamics Inc
Advicenne SA
Aequus Pharmaceuticals Inc
AfaSci Inc
Affectis Pharmaceuticals AG
AgoneX Biopharmaceuticals Inc
AMO Pharma Ltd
Anavex Life Sciences Corp
Aphios Corp
Aquestive Therapeutics Inc
Asklepios BioPharmaceutical Inc
Aucta Pharmaceuticals LLC
Axium Pharmaceuticals Inc
B&A Therapeutics
BCWorld Pharm Co Ltd
Benuvia Therapeutics Inc
Bial - Portela & Ca SA
Bio-Pharm Solutions Co Ltd
Biogen Inc
Bioinnotis
BioLink Life Sciences Inc
Biovista Inc
Bloom Science Inc
Bristol-Myers Squibb Co
Cann Pharmaceutical Australia Ltd
Catalyst Pharmaceuticals Inc
Cavion LLC
Celavie Biosciences LLC
Cellix Bio Pvt Ltd
Cerebral Therapeutics Inc
Cerecin Inc
Cerevel Therapeutics LLC
Coda Biotherapeutics Inc
CombiGene AB
Crossject SA
CuroNZ Ltd
CURx Pharmaceuticals Inc
Cypralis Ltd
Eisai Co Ltd
Encoded Therapeutics Inc
Engage Therapeutics Inc
Epalex Corp
EpyGenix Therapeutics Inc
ES Therapeutics LLC
Eton Pharmaceuticals Inc
Ferring Pharmaceuticals Inc
GABA Therapeutics Inc
Genentech Inc
Generoath Co Ltd
Genus Lifesciences Inc
Gilead Sciences Inc
Glialogix Inc
Guangzhou Cellprotek Pharmaceutical Co Ltd
GW Pharmaceuticals Plc
Harvest One Cannabis Inc
Idorsia Pharmaceutical Ltd
Ionis Pharmaceuticals Inc
Iproteos SL
JC Pharma Inc
Johnson & Johnson
Karessa Pharma Holding AB
Ketogen Inc
Knopp Biosciences LLC
LATITUDE Pharmaceuticals Inc
Lead Discovery Center GmbH
LifeSplice Pharma LLC
Marinus Pharmaceuticals Inc
Medicure Inc
Medlab Clinical Ltd
Mercaptor Discoveries Inc
MGC Pharmaceuticals Ltd
Mucodel Pharma LLC
MyX Therapeutics Inc
NeuCyte Inc
NeurAegis Inc
Neurelis Inc
NeuroAdjuvants Inc
Neurocrine Biosciences Inc
NeuroCycle Therapeutics Inc
Neuroene Therapeutics LLC
Neurolink, Inc
Neuron Biopharma SA
Neurona Therapeutics Inc
New Amsterdam Sciences Inc
Nissan Chemical Corp
NoNO Inc
NuBioPharma LLC
OB Pharmaceuticals
OPKO Health Inc
Otsuka Holdings Co Ltd
Ovid Therapeutics Inc
OWP Pharmaceuticals Inc
Pairnomix LLC
Panaxia Pharmaceutical Industries Ltd
Panorama Research Inc
Pfizer Inc
PharmatrophiX Inc
Praxis Precision Medicines Australia Pty Ltd
Promius Pharma LLC
Proniras Corp
Proveca Ltd
PTC Therapeutics Inc
Recursion Pharmaceuticals Inc
reMYND NV
RogCon Inc
Sage Therapeutics Inc
Saniona AB
Scientus Pharma Inc
Sedor Pharmaceuticals LLC
Serina Therapeutics Inc
Simcere Pharmaceutical Group
SK Biopharmaceuticals Co Ltd
Stoke Therapeutics Inc
Suda Pharmaceuticals Ltd
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Supernus Pharmaceuticals Inc
Sustained Nano Systems LLC
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Techfields Pharma Co Ltd
The Cell Factory BVBA
Therapix Biosciences Ltd
UCB SA
Ultragenyx Pharmaceutical Inc
Valerion Therapeutics LLC
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Xenon Pharmaceuticals Inc
XERIS Pharmaceuticals Inc
Xi'an Libang Pharmaceuticals Co Ltd
XW Laboratories Inc
Zhejiang Conba Pharmaceutical Co Ltd
Zogenix Inc
Zynerba Pharmaceuticals Inc